Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies

Next Previous
X
Search
Trial Profile

A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Sirexatamab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-731
  • Sponsors HealthCare Pharmaceuticals Inc; Leap Therapeutics

    • Most Recent Events

    • 09 Nov 2020 According to a Leap Therapeutics media release, data from this study were presented at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting.
    • 09 Nov 2020 Results (n=69) published in a Leap Therapeutics media release.
    • 28 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top